Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism

키워드

참고문헌 (53)

1. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)[DOI]
2. Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes", N Engl J Med, 375, pp.1834~1844 (2016)[DOI]
3. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)[DOI]
4. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)[DOI]
5. Madaan T, "Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective", Eur J Pharm Sci, 93, pp.244~252 (2016)[DOI]
6. Abdul-Ghani MA, "Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes", Endocr Rev, 32, pp.515~531 (2011)[DOI]
7. Sanchez RA, "Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease", World J Diabetes, 6, pp.1186~1197 (2015)[DOI]
8. Fitchett D, "Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial", Eur Heart J, 37, pp.1526~1534 (2016)[DOI]
9. Sonesson C, "Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis", Cardiovasc Diabetol, 15, pp.37~ (2016)[DOI]
10. Birkeland KI, "Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis", Lancet Diabetes Endocrinol, 5, pp.709~717 (2017)[DOI]
11. Kosiborod M, "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study", J Am Coll Cardiol, 71, pp.2628~2639 (2018)[DOI]
12. Wu JH, "Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 4, pp.411~419 (2016)[DOI]
13. Saad M, "Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials", Int J Cardiol, 228, pp.352~358 (2017)[DOI]
14. Inzucchi SE, "SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials", Diab Vasc Dis Res, 12, pp.90~100 (2015)[DOI]
15. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)[DOI]
16. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)[DOI]
17. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)[DOI]
18. Abdul-Ghani M, "SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study", Diabetes Care, 39, pp.717~725 (2016)[DOI]
19. Hayward RA, "Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 372, pp.2197~2206 (2015)[DOI]
20. DeFronzo RA, "The EMPA-REG study: what has it told us? A diabetologist's perspective", J Diabetes Complications, 30, pp.1~2 (2016)[DOI]
21. Sattar N, "Revisiting the links between glycaemia, diabetes and cardiovascular disease", Diabetologia, 56, pp.686~695 (2013)[DOI]
22. Giacco F, "Oxidative stress and diabetic complications", Circ Res, 107, pp.1058~1070 (2010)[DOI]
23. Dassanayaka S, "O-GlcNAc and the cardiovascular system", Pharmacol Ther, 142, pp.62~71 (2014)[DOI]
24. Ferrannini E, "Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients", J Clin Invest, 124, pp.499~508 (2014)[DOI]
25. Daniele G, "Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes", Diabetes Care, 39, pp.2036~2041 (2016)[DOI]
26. Mudaliar S, "Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis", Diabetes Care, 39, pp.1115~1122 (2016)[DOI]
27. Ferrannini E, "CV protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis", Diabetes Care, 39, pp.1108~1114 (2016)[DOI]
28. Stenlof K, "Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise", Diabetes Obes Metab, 15, pp.372~382 (2013)[DOI]
29. Bolinder J, "Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin", Diabetes Obes Metab, 16, pp.159~169 (2014)[DOI]
30. Ridderstrale M, "Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial", Lancet Diabetes Endocrinol, 2, pp.691~700 (2014)[DOI]
31. Fox CS, "Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study", Diabetes Care, 31, pp.1582~1584 (2008)[DOI]
32. Wing RR, "Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes", N Engl J Med, 369, pp.145~154 (2013)[DOI]
33. Odden MC, "Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002", Am J Kidney Dis, 64, pp.550~557 (2014)[DOI]
34. Inzucchi SE, "How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial", Diabetes Care, 41, pp.356~363 (2018)[DOI]
35. McMurray J, "EMPA-REG - the "diuretic hypothesis"", J Diabetes Complications, 30, pp.3~4 (2016)[DOI]
36. Chilton R, "Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes", Diabetes Obes Metab, 17, pp.1180~1193 (2015)[DOI]
37. Marx N, "Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus", Eur Heart J, 37, pp.3192~3200 (2016)[DOI]
38. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis", Lancet, 387, pp.435~443 (2016)[DOI]
39. Scheen AJ, "Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics", Diabetes Metab, 42, pp.224~233 (2016)[DOI]
40. Emdin CA, "Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis", JAMA, 313, pp.603~615 (2015)[DOI]
41. Cherney DZ, "Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus", Circulation, 129, pp.587~597 (2014)[DOI]
42. Titze J, "A different view on sodium balance", Curr Opin Nephrol Hypertens, 24, pp.14~20 (2015)[DOI]
43. Schmieder R, "OS 12-03 SGLT-2-inhibition with dapagliflozin reduces tissue sodium content", J Hypertens, 34, pp.e76~ (2016)
44. Tikkanen I, "Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension", Curr Opin Nephrol Hypertens, 25, pp.81~86 (2016)[DOI]
45. Muskiet MH, "Understanding EMPA-REG OUTCOME", Lancet Diabetes Endocrinol, 3, pp.928~929 (2015)[DOI]
46. Lambers Heerspink HJ, "Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes", Diabetes Obes Metab, 15, pp.853~862 (2013)[DOI]
47. Sano M, "Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys", J Clin Med Res, 8, pp.844~847 (2016)[DOI]
48. Jones BJ, "Minireview: glucagon in stress and energy homeostasis", Endocrinology, 153, pp.1049~1054 (2012)[DOI]
49. Zhou L, "Human cardiomyocytes express high level of Na+", glucose cotransporter 1 (SGLT1), 2003, pp.90, 339~346
50. Baartscheer A, "Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+", H+ exchanger in rats and rabbits, 2017, pp.60, 568~573
51. Hamouda NN, "Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats", Mol Cell Biochem, 400, pp.57~68 (2015)[DOI]
52. Lin B, "Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice", Cardiovasc Diabetol, 13, pp.148~ (2014)[DOI]
53. Kusaka H, "Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome", Cardiovasc Diabetol, 15, pp.157~ (2016)[DOI]

관련 논문AI추천